This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, Institut Curie, Université Pierre Et Marie Curie. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 5,383 
1 out of 163 
1 out of 74 Years Active: 2010
Title: Stamatios E Theocharis: Innovator in Cancer Prognosis
Introduction
Stamatios E Theocharis is a notable inventor based in Athens, Greece. He has made significant contributions to the field of cancer research through his innovative methods and techniques. His work focuses on the assessment of cell proliferation, which is crucial for cancer prognosis and diagnosis.
Latest Patents
Stamatios E Theocharis holds a patent for "Proliferation markers in clinical practice and their use for cancer prognosis or diagnosis." This invention relates to a method for assessing the proliferative state of cells in human or non-human biological samples. It utilizes Chromatin Assembly Factor-1 (CAF-1) subunits as proliferation markers. This method is particularly valuable for cancer prognosis, diagnosis, and monitoring tumor response to therapy. He has 1 patent to his name.
Career Highlights
Throughout his career, Stamatios has worked with prestigious institutions, including Université Pierre Et Marie Curie and Institut Curie. His research has contributed to advancements in understanding cancer biology and improving clinical practices.
Collaborations
Stamatios has collaborated with esteemed colleagues such as Genevieve Almouzni and Sophie E Polo. Their joint efforts have furthered research in the field of cancer and cell biology.
Conclusion
Stamatios E Theocharis is a prominent figure in cancer research, with a focus on innovative methods for assessing cell proliferation. His contributions have the potential to enhance cancer diagnosis and treatment, making a significant impact in the medical field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile